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ABSTRACT
Background: In 2014, guidelines from the National
Institute for Health and Care Excellence (NICE)
provided updated recommendations on lipid-modifying
therapy (LMT). We assessed clinical practice
contemporaneous to release of these guidelines in a
UK general practice setting for secondary and high-risk
primary-prevention populations, and extrapolated the
findings to UK nation level.
Methods: Patients from The Health Improvement
Network database with the following criteria were
included: lipid profile in 2014 (index date); ≥20 years
of age; ≥2 years representation in database prior to
index; ≥1 statin indication either for atherosclerotic
cardiovascular disease (ASCVD) or the non-ASCVD
conditions high-risk diabetes mellitus and/or chronic
kidney disease.
Results: Overall, 183 565 patients met the inclusion
criteria (n=91 479 for ASCVD, 92 086 for non-ASCVD).
In those with ASCVD, 79% received statin treatment
and 31% received high-intensity statin. In the non-
ASCVD group, 62% were on a statin and 57% received
medium-intensity or high-intensity statin. In the ASCVD
and non-ASCVD cohorts, 6% and 15%, respectively,
were already treated according to dosing
recommendations as per updated NICE guidelines.
Extrapolation to the 2014 UK population indicated that,
of the 3.3 million individuals with ASCVD, 2.4 million
would require statin uptitration and 680 000 would
require statin initiation (31% de novo initiation, 60%
reinitiation, 9% addition to non-statin LMT) to achieve
full concordance with updated guidelines. Of the 3.5
million high-risk non-ASCVD individuals, 1.6 million
would require statin uptitration and 1.4 million would
require statin initiation (59% de novo initiation, 36%
reinitiation, 5% addition to non-statin LMT).
Conclusions: A large proportion of UK individuals
with ASCVD and high-risk non-ASCVD received statin
treatment (79% and 62%, respectively) during the year
of NICE 2014 guidelines release. Up to 94% of patients
with ASCVD and 85% of high-risk non-ASCVD
individuals, representing ∼3 million individuals in each
group, would require statin uptitration or initiation to
achieve full concordance with updated guidelines.
Strengths and limitations of this study
▪ Potential implications of the 2014 National
Institute for Health and Care Excellence (NICE)
lipid-modification therapy guidelines on clinical
practice in the UK have not been evaluated in
prior reports.
▪ We analysed a cohort of high-risk patients repre-
senting the UK general practice from a large
representative data source and developed esti-
mates of the extrapolated number of individuals
across the UK, including subgroups of interest,
whose treatment was already concordant with
the new guidelines and those for whom uptitra-
tion or initiation of statin therapy would be
needed to achieve full concordance.
▪ Our study provides novel data on clinical practice
in many high-risk subgroups such as those with
ischaemic stroke, peripheral arterial disease,
diabetes without vascular disease and chronic
kidney disease.
▪ A limitation of the study is that though the defin-
ition of medication usage was optimised to
provide valid point-in-time estimates concurrent
with lipid measurements, whether patients actu-
ally took their medications as prescribed cannot
be ensured from the data source.
▪ The aim of the study was to provide a compari-
son of 2014 clinical practice relative to guidelines
released in 2014; these results cannot be inter-
preted in terms of the impact of the new guide-
lines on clinical practice.
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INTRODUCTION
Despite a decade of continuing decline in cardiovascular
(CV) disease mortality, CV deaths remain the leading
cause of mortality in the UK, accounting for ∼31% of all
deaths, with ischaemic heart disease and stroke repre-
senting the vast majority (17% and 10%, respectively).1 2
Reducing low-density lipoprotein cholesterol (LDL-C)
with statin therapy has been shown to reduce all-cause
and CV mortality, as well as CV outcomes such as
non-fatal myocardial infarction (MI), coronary revascu-
larisation procedures, and non-fatal ischaemic stroke in
populations with prior atherosclerotic CV disease
(ASCVD) and in certain primary-prevention popula-
tions.3 4 The high tolerability and safety of statins have
also been established across these subgroups.3–5 Despite
this, appropriate statin use and atherogenic lipid level
reduction remain suboptimal in clinical practice.6
Statins are recommended by the National Institute for
Health and Care Excellence (NICE) as ﬁrst-line lipid-
modifying therapy (LMT) for the reduction of CVevent risk
in patients with ASCVD as well as diabetes mellitus (DM),
familial hypercholesterolaemia, chronic kidney disease
(CKD) and other high-risk primary-prevention popula-
tions.7 In line with evidence from randomised trials and the
recent availability of generic atorvastatin, the 2014 NICE
guidelines recommend more intensive statin therapy com-
pared with the 2008 guidelines. The recommended regi-
mens include atorvastatin 80 mg for patients with ASCVD
and atorvastatin 20 mg or higher for those with most other
high-risk conditions; although lower doses of atorvastatin
can be used in cases of potential drug to drug interactions,
high risk of adverse effects or patient preference.
The present study assessed real-world clinical practice in
2014 relative to the updated NICE guidelines. In a large,
representative UK population, we analysed LMT usage for
each of the following indications: recent acute coronary
syndrome (ACS), other coronary heart disease (CHD),
ischaemic stroke/transient ischaemic attack (TIA), periph-
eral arterial disease (PAD), type 1 (T1) DM, type 2 (T2)
DM and CKD. We provide an estimate of the extrapolated
number of individuals in the UK within each subgroup
whose treatment was already concordant with the guide-
lines as well as those for whom uptitration or initiation of
statin therapy would be needed for full concordance. For
the same patient subgroups, we also evaluated achievement
of LDL-C and non-high-density lipoprotein cholesterol
(non-HDL-C) goals as deﬁned by the 2011 European
Society of Cardiology (ESC)/European Atherosclerosis
Society (EAS) lipid management guidelines.8
METHODS
This study was based on a retrospective, cross-sectional
and observational cohort.
Database and cohort selection
We used the The Health Improvement Network (THIN)
database, which represents anonymised patient records
from general practitioners (GPs) in the UK. As of the
end of 2014, the database represented 422 active GP
practices and 3.5 million unique active patients. The
THIN database has been found to be broadly represen-
tative of the UK population, and the validity of recorded
information has been established in previous studies,9 10
including the validity of using Read codes to identify
ASCVD, other high CV risk conditions and incident CV
events.11 12 Owing to the extensive use of GP electronic
prescribing in the UK, the recording of prescriptions is
expected to be complete and accurate.13 Furthermore,
the scope of THIN data to inform complex epidemio-
logical observations was supported by the validation of
the updated QRISK2 model for estimating the 10-year
incident risk of CV disease in the UK general
population.14
The following inclusion criteria were used: presence
of a lipid proﬁle measurement in 2014 (last LDL-C
measurement in 2014 was considered the index date);
≥20 years of age and presence of ≥1 high CV risk condi-
tion for which statins would be recommended as per
NICE guidelines (see below). In order to ensure
complete capture of pertinent demographic and clinical
characteristics, and to assess for prior statin use among
those not currently treated with statins, we also required
continuous representation in the database for ≥2 years
prior to the index date.
Determination of ASCVD and non-ASCVD categories
NICE 2014 guidelines recommend statin treatment in
following groups: (1) ASCVD, where atorvastatin 80 mg
is recommended; (2) T2DM with QRISK2 10-year risk
≥10%, where atorvastatin 20 mg is recommended; (3)
T1DM with age >40 years or DM duration of >10 years
or presence of nephropathy or other CV risk factors,
where atorvastatin 20 mg is recommended; (4) CKD,
where atorvastatin 20 mg is recommended and (5) all
other individuals with QRISK2 10-year risk ≥10%, where
atorvastatin 20 mg is recommended. Our overall study
cohort represents groups 1–4 (excluding 5), with group
1 representing the ASCVD population and groups 2–4
representing a high-risk non-ASCVD population.
ASCVD and non-ASCVD conditions were identiﬁed
using standardised Read codes (see online
supplementary table S1) as follows: (1) recent ACS (MI
or unstable angina within 12 months prior to index
date); (2) other CHD (eg, ACS >12 months prior to
index date, any coronary revascularisation, stable angina
or ischaemic cardiomyopathy); (3) ischaemic stroke or
TIA; (4) PAD (presence of revascularisation/surgery for
signiﬁcant peripheral arterial, aortic or carotid disease);
(5) T2DM with QRISK2 10-year risk ≥10%; (6) T1DM
with age >40 years (represents a slight simpliﬁcation of
guideline criteria with application of only the age limit)
and (7) CKD stage III–V (estimated glomerular ﬁltration
rate <60 mL/min/1.73 m2 or dialysis, herewith referred
to as ‘CKD’). A thorough process involving clinical cardi-
ology and coding expert review was undertaken to
2 Steen DL, et al. BMJ Open 2017;7:e013255. doi:10.1136/bmjopen-2016-013255
Open Access
 o
n
 21 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-013255 on 17 February 2017. Downloaded from 
optimise the speciﬁcity of Read codes for each condi-
tion. Read codes were also used to identify non-CV
comorbidities. The QRISK2 10-year risk was estimated
for individuals with T2DM in the non-ASCVD cohort via
application of the algorithm to patient-level data (details
available in online supplementary appendix).14
Patients with conditions 1–4 were collectively referred
to as ‘ASCVD’, while those with only conditions 5–7
were collectively referred to as ‘non-ASCVD’. Those with
ASCVD were categorised hierarchically (as above) into
four mutually exclusive groups: (1) recent ACS; (2)
other CHD; (3) ischaemic stroke/TIA and (4) PAD. A
sensitivity analysis was also conducted by categorising
these same patients by each condition present, referred
to as prevalent disease categorisation. As an example, an
individual with a history of elective coronary revasculari-
sation and PAD would be categorised hierarchically as
‘other CHD’, but as ‘other CHD’ and ‘PAD’ under the
prevalent disease categorisation. Patients without ASCVD
were categorised into ﬁve mutually exclusive categories
to better evaluate the association of speciﬁc conditions
with LMT usage and lipid goal achievement. These
categories were: (1) T2DM and QRISK2 ≥10% with
CKD; (2) T2DM and QRISK2 ≥10% without CKD; (3)
T1DM and age >40 years with CKD; (4) T1DM and age
>40 years without CKD and (5) other CKD not meeting
the criteria of the other categories. For enhanced read-
ability, we omitted the qualiﬁer QRISK2 10-year risk
≥10% from the non-ASCVD T2DM population, and age
>40 years from the non-ASCVD T1DM population,
considering them implicit in the deﬁnitions. The ﬁfth
category was referred to as ‘CKD alone’.
Determination of medication treatment
For any particular medication, patients were considered to
have been treated on the index date if the medication
supply via a recorded prescription was present on or
within 30 days prior to the index date, regardless of the
duration of the prescription (ﬁgure 1). This point-in-time
assessment approach was used to better control for factors
such as discontinuation over time. In addition, this also
ensured that lipid levels best reﬂected the impact of the
treatment regimen as the assessment of both measures was
concurrent. Those not treated on the index date but with
evidence of a prior recorded prescription were considered
to have a history of being treated. Those without any
evidence of a recorded prescription for a medication
within the 2 years prior to the index date were considered
to have no documented history of being treated. LMTwas
categorised as high-intensity, medium-intensity and low-
intensity statin therapy, as well as non-statin therapy (see
online supplementary table S2).7
We also summarised statin usage as per 2014 NICE
guideline recommendations, which recommend treat-
ment with atorvastatin 80 mg and 20 mg in patients with
ASCVD and patients without ASCVD, respectively (for
our study, we interpreted this as regimens of equivalent
or higher potency: atorvastatin 80 mg equivalent or
higher (atorvastatin 80 mg, rosuvastatin 40 mg); and
atorvastatin 20 mg equivalent or higher (atorvastatin 20,
40 and 80 mg, rosuvastatin 10, 20 and 40 mg and simvas-
tatin 80 mg)). It should be noted, however, that guide-
lines allow for a consideration of a lower dose of
atorvastatin in presence of drug interactions, risk of
adverse effects or patient preference. Statin categories
included statins administered as either monotherapy or
in combination with ≥1 non-statin medications.
Determination of LDL-C and non-HDL-C levels
We assessed the achievement of LDL-C and non-HDL-C
levels relative to the ESC/EAS 2011 guidelines. They
recommend goals of LDL-C <1.8 mmol/L (70 mg/dL)
and non-HDL-C <2.6 mmol/L (100 mg/dL) for the
ASCVD and non-ASCVD populations reported in the
current study.8
Patient involvement
Our study was based on an analysis of patient-level data
represented in an electronic medical record (EMR)
database used by a set of GPs in the UK using the Vision
EMR software. In order to protect patient privacy, the
analyses reported in our study are based on a
de-identiﬁed version of the database where patient iden-
tiﬁers are encrypted such that it is not possible to link
Figure 1 Determination of
treatment status as of the index
date. Blue bars representing
scenarios A and B (medication
supply via recorded prescription
(Rx) on or within 30 days prior to
the index date) define the patient
as being treated as of the index
date. The red bar representing
scenario C (medication supply via
recorded Rx more than 30 days
prior to the index date) defines
the patient as not being treated
as of the index date.
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an individual patient in the data set to a speciﬁc individ-
ual in the real world. As such, our study did not involve
any direct patient-level interaction.
Statistical analyses
All statistical analyses were descriptive in nature. Cohort
characteristics, LMT usage and achieved LDL-C and
non-HDL-C levels were summarised via proportions and
mean±SD as appropriate. Findings on number of
patients treated with LMT were extrapolated to the UK
population via an adjusted extrapolation methodology
that accounted for differential weights by clinical and
demographic proﬁles (details available in online
supplementary appendix). All analyses were conducted
with SAS software V.9.4.
RESULTS
The inclusion criteria were met by 183 565 patients, of
whom approximately one-half (n=91 479) had estab-
lished ASCVD, with the remainder (n=92 086) having
non-ASCVD high-risk conditions (ﬁgure 2). According
to hierarchical disease categorisation for the ASCVD
group, 3% had a recent ACS, 64% had another CHD
diagnosis, 22% had a history of ischaemic stroke/TIA
and 11% had PAD. Approximately one-third of the
ASCVD cohort had concomitant DM; and close to one-
fourth had concomitant CKD. Baseline characteristics
of the ASCVD group by hierarchical categorisation are
presented in table 1 and by prevalent categorisation in
online supplementary table S3. Baseline characteristics
for the non-ASCVD group are also presented in table 1.
In the non-ASCVD group, 12% had T2DM with CKD;
57% had T2DM without CKD; 1% had T1DM with
CKD; 5% had T1DM without CKD and 25% had CKD
alone.
LMT usage in 2014
ASCVD population
Approximately 79% of the ASCVD population received
treatment with a statin on the index date (table 2). By
hierarchical categories, statin use was 87% in the recent
ACS group, 82% in the other CHD group and 73% in
the ischaemic stroke/TIA and PAD groups. Of patients
currently treated with statins, 40% were receiving treat-
ment with high-intensity statins (deﬁned as per online
supplementary table S2): 72% for recent ACS, 42% for
other CHD, 32% for PAD and 29% for ischaemic
stroke/TIA. Statins were predominantly used as mono-
therapy: 92% for high-intensity statins, 98% for
medium-intensity statins and 96% for low-intensity
statins. Of patients not currently treated with LMT, 34%
had no evidence of any LMT treatment in the 2 years
prior to the index date. LMT usage by prevalent categor-
isation in the ASCVD group is presented in online
supplementary table S4.
Non-ASCVD population
In the non-ASCVD population, 62% received treatment
with a statin on the index date (table 2). In the sub-
groups, statin use was 71% in T2DM with CKD, 66% in
T2DM without CKD, 73% in the T1DM with CKD, 62%
in T1DM without CKD and 49% in CKD alone. Of the
patients receiving statins, at least a medium-intensity
statin was used in 92%. As with patients with ASCVD,
statins were most commonly used as monotherapy: 93%
for high-intensity statins and 98% for medium-intensity
and low-intensity statins. Of patients not currently
Figure 2 Flow chart of the
cohort selection for the study.
*ASCVD includes acute coronary
syndrome, other coronary heart
disease, ischaemic stroke/
transient ischaemic attack and
peripheral arterial disease.
†Includes type 2 diabetes mellitus
with QRISK2 ≥10%, type 1
diabetes mellitus with age
>40 years and chronic kidney
disease not meeting the previous
diabetes mellitus criteria. ASCVD,
atherosclerotic cardiovascular
disease; CV, cardiovascular
disease; THIN, The Health
Improvement Network.
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Table 1 Baseline characteristics for the overall ASCVD and non-ASCVD cohorts and subgroups
ASCVD cohort (n=91 497) Non-ASCVD cohort (n=92 086)
Recent ACS
(3%)
Other CHD
(64%)
Ischaemic
stroke/TIA
(22%)
PAD
(11%)
Total
ASCVD
T2DM with
CKD (12%)
T2DM without
CKD (57%)
T1DM with
CKD (1%)
T1DM without
CKD (5%)
CKD alone
(25%)
Total
non-ASCVD
Demographic characteristics
Age, mean, years 67.8 72.8 73.0 72.3 72.6 75.7 67.2 69.7 57.2 74.6 69.7
Male, % 66.5 63.5 50.3 62.8 60.7 41.3 58.6 40.7 57.6 35.0 50.3
SDI*, mean 2.7 2.7 2.6 2.8 2.7 2.7 2.8 2.7 2.6 2.6 2.7
Current smoker, % 15.2 12.1 13.5 26.6 14.1 7.0 14.9 10.8 16.3 7.1 11.9
BMI, mean, kg/m2 28.4 28.6 27.8 27.6 28.3 30.4 30.9 29.8 28.3 28.3 30.1
Systolic BP, mean 128.9 131.5 133.1 134.6 132.1 134.5 134.7 134.7 131.1 134.1 134.3
Baseline clinical characteristics
Recent ACS, % 100.0 0.0 0.0 0.0 3.4 N/A N/A N/A N/A N/A N/A
Other CHD, % 64.2 100.0 0.0 0.0 66.0 N/A N/A N/A N/A N/A N/A
Ischaemic stroke/TIA, % 7.6 10.5 100.0 0.0 28.6 N/A N/A N/A N/A N/A N/A
PAD, % 10.1 11.2 14.0 100.0 21.7 N/A N/A N/A N/A N/A N/A
DM, % 27.0 30.1 25.6 33.7 29.4 100.0 100.0 100.0 100.0 7.1 76.3
Hypertension, % 50.4 61.5 62.1 64.2 61.5 77.4 62.2 74.4 41.8 73.2 66.0
History of CHF, % 14.0 11.2 4.2 5.1 9.1 1.4 0.5 6.9 1.0 7.1 2.4
CKD, stage III, % 17.2 24.4 22.1 23.0 23.5 100.0 0.0 100.0 0.0 100.0 38.2
CKD, stage IV–V, %‡ 0.2 0.3 0.2 0.3 0.2 1.2 0.0 2.0 0.0 0.8 0.3
Concomitant medication use§
β-blockers, % 81.4 60.1 23.5 22.4 48.7 N/A N/A N/A N/A N/A N/A
ACEI/ARBs, % 85 65.3 52.1 52.4 61.7 74.6 59.3 77.8 52.7 59.9 61.1
Antiplatelets, %¶ 52.5 13.5 29.7 15.4 18.5 N/A N/A N/A N/A N/A N/A
ASCVD subgroups represent hierarchical categorisation. Non-ASCVD categorisations have been simplified by consideration of the qualifiers QRISK2 ≥10% and age >40 years as implicit in the
definitions of T2DM and T1DM, respectively, with and without CKD, and of the qualifiers without T2DM + QRISK2 ≥10% or T1DM + age >40 as implicit in the definition of CKD alone.
*Social deprivation index (SDI) as defined by the Townsend deprivation index score analysed in quintiles, 1=most affluent and 5=least affluent.
†Includes Indian, Pakistani, Bangladeshi and other South Asian individuals.
‡Stage V CKD includes end-stage renal disease and dialysis.
§Medication use on index date.
¶Clopidogrel/ticagrelor/prasugrel.
ACEI, ACE inhibitors; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BMI, Body Mass Index; BP, blood pressure; CHD,
coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; DM, diabetes mellitus; N/A, not applicable; PAD, peripheral arterial disease; SDI, Social Deprivation Index;
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.
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Table 2 Use of LMT in the overall ASCVD and non-ASCVD cohorts and subgroups
ASCVD cohort (n=91 497) Non-ASCVD cohort (n=92 086)
Recent
ACS
Other
CHD
Ischaemic
stroke/TIA PAD
Total
ASCVD
T2DM
with CKD
T2DM
without
CKD
T1DM
with
CKD
T1DM
without
CKD
CKD
alone
Total
non-ASCVD
High-intensity statin, %* 62.4 34.6 21.5 23.2 31.4 20.0 18.6 29.0 21.1 11.1 17.0
Monotherapy, % 93.3 91.8 93.2 92.3 92.2 91.1 93.5 92.6 90.2 93.3 93.0
Plus ezetimibe, % 1.0 4.8 2.9 3.4 4.1 3.2 2.4 4.1 5.1 2.7 2.8
Plus other non-statin LMT, % 5.8 3.4 3.9 4.3 3.7 5.7 4.0 3.2 4.7 4.0 4.3
Medium-intensity statin, %* 22.6 41.4 46.2 44.3 42.1 44.7 43.0 39.5 36.5 33.1 40.4
Monotherapy, % 98.6 97.9 98.7 98.6 98.2 97.9 98.4 96.3 97.7 98.9 98.4
Plus ezetimibe, % 0.6 1.2 0.7 0.6 1.0 0.6 0.6 1.7 1.4 0.5 0.6
Plus other non-statin LMT, % 0.9 0.9 0.5 0.8 0.8 1.5 1.0 2.0 1.0 0.7 1.0
Low-intensity statin, %* 2.1 5.9 5.5 5.1 5.6 6.4 4.9 4.9 4.4 4.8 5.0
Monotherapy, % 93.8 95.9 97.4 97.1 96.3 96.2 98.1 89.2 95.6 98.3 97.7
Plus ezetimibe, % 6.3 3.2 1.7 2.3 2.8 2.3 1.1 8.1 2.7 1.0 1.4
Plus other non-statin LMT, % 0.0 0.9 0.8 0.6 0.8 1.6 0.7 2.7 1.6 0.7 0.9
Non-statins only, %* 0.9 2.0 1.7 1.9 1.9 2.5 1.6 3.9 2.0 1.7 1.8
Ezetimibe, % 70.4 61.3 65.5 55.6 61.6 47.9 54.2 58.6 61.6 45.5 51.5
Other non-statin LMT, % 29.6 38.7 34.5 44.4 38.4 52.1 45.8 41.4 38.4 54.5 48.5
Not currently treated by LMT, %* 12.1 16.2 25.1 25.4 19.0 26.4 31.9 22.7 35.9 49.4 35.8
Prev high-intensity statin, % 20.7 16.4 8.6 9.3 13.2 7.7 6.1 18.2 9.1 3.3 5.5
Prev medium-intensity statin, % 22.8 40.9 37.9 33.0 38.4 33.2 27.5 30.6 29.9 17.7 24.7
Prev low-intensity statin, % 5.6 10.0 6.9 6.8 8.5 7.3 4.9 10.0 4.4 3.9 4.7
Prev non-statin LMT, % 4.8 7.2 4.8 3.6 5.9 6.1 3.5 5.3 3.8 2.4 3.4
No prev LMT, % 46.1 25.5 41.8 47.3 34.0 45.7 58.0 35.9 52.8 72.7 61.7
*Numbers in this row denote absolute percentages, and add up to 100% vertically. All other numbers are relative percentages of the absolute percentages. ASCVD subgroups represent
hierarchical categorisation. Non-ASCVD categorisations have been simplified by consideration of the qualifiers QRISK2 ≥10% and age >40 years as implicit in the definitions of T2DM and
T1DM, respectively, with and without CKD, and of the qualifiers without T2DM + QRISK2 ≥10% or T1DM + age >40 as implicit in the definition of CKD alone.
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CKD, chronic kidney disease; LMT, lipid-modifying therapy; PAD, peripheral
arterial disease; Prev, previously on; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.
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treated with LMT, 62% had no evidence of any LMT
treatment in the 2 years prior to the index date.
Comparison of LMT usage in 2014 with 2014 NICE
recommendations
ASCVD population
Statin treatment already concordant with the NICE 2014
guidelines (atorvastatin 80 mg equivalent or higher;
which is a subset of statins regarded as high-intensity)
was observed in 6% of the ASCVD cohort, with 73%
treated with a less intensive statin regimen than recom-
mended and 21% not treated with any statin (table 3).
Extrapolated to the UK ASCVD population, this identi-
ﬁed ∼202 000 individuals whose treatment was already
concordant with the updated guidelines, 2.4 million
who would require statin uptitration, and 680 000 in
whom statin initiation would be recommended to
achieve full concordance. For those requiring statin initi-
ation, 31% represented a need for de novo initiation,
60% reinitiation due to past discontinuation and 9%
statin addition to non-statin LMT. NICE 2014 guidelines
recommended statin therapy was most commonly used
in patients with a recent ACS (33%) and the least used
in patients with history of an ischaemic stroke/TIA or
PAD (2% each).
Non-ASCVD population
Statin treatment already concordant with the NICE 2014
guidelines (atorvastatin 20 mg equivalent or higher) was
observed in 15% of the non-ASCVD cohort, with 47%
treated with a less intensive statin regimen than recom-
mended and 37% not treated with any statin (table 3).
Extrapolation identiﬁed ∼508 000 UK patients without
ASCVD (ie, fulﬁlling the DM and/or CKD indications)
whose treatment was already concordant with the
updated guidelines, 1.6 million who would require upti-
tration, and 1.4 million in whom statin initiation would
be recommended to achieve full concordance. For those
requiring statin initiation, 59% represented a need for de
novo initiation, 36% reinitiation due to past discontinu-
ation and 5% statin addition to non-statin LMT. Of the
subgroups, T1DM with CKD was most likely to already be
receiving NICE 2014 guidelines recommended statin
therapy (26%) and CKD alone was least likely (10%).
ESC/EAS-recommended lipid goal achievement
ASCVD population
The mean LDL-C was 2.3 mmol/L with ∼31% achieving
a LDL-C <1.8 mmol/L. Mean non-HDL-C was
2.9 mmol/L with ∼42% achieving a non-HDL-C
<2.6 mmol/L. Online supplementary tables S5 and S6
provide a detailed summary of the mean LDL-C and
non-HDL-C levels, achievement of LDL-C <1.8 mmol/L
and non-HDL-C <2.6 mmol/L, by LMT treatment for
prevalent and hierarchical subgroups. Achievement of
LDL-C and non-HDL-C goals was associated with the
hierarchy of ASCVD subgroups, with recent ACS being
the highest and PAD being the lowest. Patients with
recent ACS receiving high-intensity statins had the
highest achievement of both lipid goals: LDL-C
<1.8 mmol/L was 53% and non-HDL-C <2.6 mmol/L
was 65%. LDL-C and non-HDL-C goal achievement by
LMT regimen was somewhat difﬁcult to interpret due to
the unadjusted nature of analyses and potential self-
selection bias, resulting from the choice of LMT
regimen in clinical practice being inﬂuenced by baseline
lipid levels and other patient-level factors.
Non-ASCVD population
Mean LDL-C was 2.4 mmol/L with ∼26% achieving
LDL-C <1.8 mmol/L. Mean non-HDL-C was 3.2 mmol/L
with ∼33% achieving non-HDL-C <2.6 mmol/L. A
summary of mean LDL-C and non-HDL-C levels and
lipid goal achievement are presented in online
supplementary table S7. Achievement of LDL-C and
non-HDL-C goals was highest for the T1DM with CKD
subgroup and lowest for the CKD alone subgroup. The
T1DM with CKD subgroup receiving medium-intensity
statins had the highest lipid goal achievement: 52% for
LDL-C <1.8 mmol/L and 69% for non-HDL-C
<2.6 mmol/L.
DISCUSSION
The use of statins for reducing atherogenic lipid levels is
recommended across all global guidelines for the
prevention of incident ASCVD events. Recent guidelines
have shifted towards an approach of consistent and
immediate initiation of the appropriate statin intensity
regimen for a particular indication regardless of baseline
lipid levels. In contrast, the standard approach has been
to lower LDL-C (or non-HDL-C) below deﬁned thresh-
olds. Our study, representing a UK general practice
population at high risk for ASCVD events, provides
several insights regarding the state of concordance of
2014 clinical practice with the updated NICE 2014
guidelines,7 which focus on the intensity of the statin
regimen. As a comparison, we also report on concord-
ance with the ESC/EAS 2011 guidelines,8 which focus
on treatment to deﬁned LDL-C goals.
We observed that 79% of individuals with ASCVD were
receiving statin treatment, with 6% being prescribed a
regimen already concordant with the NICE 2014 guide-
lines (atorvastatin 80 mg or equivalent). For the
non-ASCVD group, we observed that 62% were receiving
statin treatment, with 15% being prescribed a regimen
already concordant with the NICE 2014 guidelines (at
least atorvastatin 20 mg or equivalent). Extrapolation of
these ﬁndings to the UK population indicated that, out
of 3.3 million individuals with ASCVD, 2.4 million would
require uptitration of statin therapy and 680 000 would
require statin initiation (31% de novo initiation, 60%
reinitiation and 9% addition to non-statin LMT) to have
full population-level concordance with these recommen-
dations. Of the 3.5 million individuals with high-risk
non-ASCVD (ie, fulﬁlling DM-based and/or CKD-based
Steen DL, et al. BMJ Open 2017;7:e013255. doi:10.1136/bmjopen-2016-013255 7
Open Access
 o
n
 21 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-013255 on 17 February 2017. Downloaded from 
Table 3 Statin treatment according to NICE guidelines in the overall ASCVD and non-ASCVD cohorts and subgroups
ASCVD cohort (n=91 497) Non-ASCVD cohort (n=92 086)
Recent
ACS
Other
CHD
Ischaemic
stroke/TIA PAD
Total
ASCVD
T2DM with
CKD
T2DM without
CKD
T1DM with
CKD
T1DM without
CKD
CKD
alone
Total
non-ASCVD
Study cohort, %
Treated as per NICE
guidelines*
33.1 6.7 2.0 2.2 6.1 18.6 17.2 26.2 19.3 10.3 15.8
Treated with statins of lower
potency*
54.0 75.1 71.2 70.5 73.0 52.5 49.3 47.3 42.7 38.6 46.6
Treated with only non-statin
LMT
0.9 2.0 1.7 1.9 1.9 2.5 1.6 3.9 2.0 1.7 1.8
Not treated by LMT 12.1 16.2 25.1 25.4 19.0 26.4 31.9 22.7 35.9 49.4 35.8
Adjusted extrapolation to the UK population, N
Treated as per NICE
guidelines*
34 085 147 215 15 653 4869 201 822 112 119 209 589 10 642 18 830 156 621 507 801
Treated with statins of lower
potency*
55 615 1 639 122 550 930 158 966 2 404 633 316 269 600 916 19 220 41 649 586 243 1 564 297
Treated with only non-statin
LMT
894 44 456 13 266 4318 62 934 15 311 19 897 1575 1994 26 006 64 783
Not treated by LMT 12 488 352 657 194 365 57 299 616 809 159 085 388 359 9230 35 017 749 786 1 341 477
ASCVD subgroups represent hierarchical categorisation. Non-ASCVD categorisations have been simplified by consideration of the qualifiers QRISK2 ≥10% and age >40 years as implicit in the
definitions of T2DM and T1DM, respectively, with and without CKD, and of the qualifiers without T2DM + QRISK2 ≥10% or T1DM + age >40 as implicit in the definition of CKD alone.
*NICE 2014 guidelines recommend atorvastatin 80 mg and 20 mg, respectively, for the ASCVD and non-ASCVD populations in the table. We have included statins of equivalent or higher
potency with ASCVD definition based on atorvastatin 80 mg, rosuvastatin 40 mg and non-ASCVD definition based on atorvastatin 20, 40 and 80 mg, rosuvastatin 10, 20 and 40 mg and
simvastatin 80 mg. It should be noted that NICE guidelines allow for consideration of a lower dose based on clinical considerations and patient preference.
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CKD, chronic kidney disease; LMT, lipid-modifying therapy; NICE, National
Institute for Health and Care Excellence; PAD, peripheral arterial disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TIA, transient ischaemic attack.
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guideline criteria), 1.6 million would require uptitration
of statin therapy and 1.4 million would require statin ini-
tiation (59% de novo initiation, 36% reinitiation and 5%
addition to non-statin LMT).
Our ﬁndings highlight a considerable gap between the
2014 UK clinical practice and achievement of full
concordance with the NICE 2014 guideline recommen-
dations. Optimising the implementation of the guidelines
represents best practice and would result in a reduction
in ASCVD event risk. The practical impact on patients,
and in particular GPs, however, merits consideration.
First, for patients who are well established on a treatment
regimen, changes in therapy can lead to reduced compli-
ance, greater reporting of adverse events and additional
time within the healthcare system to monitor the changes
in therapy. Second, in an environment where primary
care is already stretched, the impact of counselling 90%
of eligible patients for statin regimen changes is likely to
be considerable on time and resources available in
primary care without, for instance, an increase in the
number of GPs. Finally, as cholesterol targets no longer
appear in the updated 2014/2015 Quality Outcomes
Framework (QOF) in the UK for rewarding the provision
of quality of care by GPs,15 and with QOF lacking
mention of statin intensity, it is unclear how narrowing of
the gap between guidelines and clinical practice might
be effectively incentivised.
As mentioned earlier, an alternative approach to
atherogenic lipid management is to aim for lipid goal
achievement as recommended in the ESC/EAS guide-
lines. For the ASCVD population, we observed that
achievement of LDL-C <1.8 mmol/L and non-HDL-C
<2.6 mmol/L8 was only 31% and 42% overall; 38% and
52% for those on medium-intensity statins; and 37% and
48% for those on high-intensity statins. Comparatively,
lower goal achievement for those on high-intensity statin
likely reﬂected the unadjusted nature of analysis, with
patients on high-intensity statins likely starting with
higher baseline lipid levels. For the non-ASCVD popula-
tion considered in the analysis (ie, fulﬁlling DM-based
and/or CKD-based guideline criteria), the ESC/EAS
guidelines recommend the same thresholds of
<1.8 mmol/L and <2.6 mmol/L for LDL-C and non-
HDL-C, respectively.8 We observed achievement of these
goals in only 26% and 33% of the patients without
ASCVD; 40% and 49% for those on medium-intensity
statin and 36% and 42% for those on high-intensity
statin.
For those not on any statin, treatment with a
medium-intensity statin is expected to lower LDL-C by
35%, while for those on medium-intensity statin, increas-
ing the dose to high-intensity statin is expected to lower
LDL-C by an incremental 15%.7 Given that average
LDL-C levels for those not on a statin in ASCVD and
non-ASCVD cohorts was ∼3.0 mmol/L, and for those on
medium-intensity statins in ASCVD and non-ASCVD
cohorts was ∼2.0 mmol/L, it is unlikely that an average
LDL-C of <1.8 mmol/L can be achieved in these
populations even by maximising statin treatment. From
the perspective of a treat to LDL-C goal approach, our
results suggest an expanded role for evidence-based
add-on therapies for LDL-C lowering, primarily
ezetimibe based on available data from the IMProved
Reduction of Outcomes: Vytorin Efﬁcacy International
Trial (IMPROVE-IT) in 2014.16
Prior reports from a generalisable UK population
describing LMT usage and lipid attainment in ASCVD
and non-ASCVD cohorts are limited. Our study provides
novel data on how these populations are treated and
how effective the treatment has been. The recent
EUROpean Action on Secondary and Primary preven-
tion by Intervention to Reduce Events (EUROASPIRE)
IV Study, representing the 2012–2013 time period, was
conducted in patients with a history of hospitalisation
due to a coronary event with an assessment date of
6 months to 3 years post event.17 The study reported
LDL-C <1.8 mmol/L achievement as only 19%. To the
best of our knowledge, the most recent study that
reported statin use in a generalisable UK population at
high CV risk found statin use in 2007 as 72% for patients
with a history of MI or coronary revascularisation and
36% for those with a history of angina but not MI.18
Statin use in the UK in those with ASCVD without cor-
onary conditions (eg, ischaemic stroke or PAD) appears
to be even further under-reported. From 1995–2005, in
individuals aged ≥50 years with a history of stroke (not
limited to ischaemic stroke), 32% of men and 26% of
women were receiving treatment with LMT.19 Data on
statin use in individuals with DM or CKD without
ASCVD also do not appear to be well reported. During
2006–2008, a diabetes registry representing GPs in
Scotland found 68% individuals with DM without
ASCVD were prescribed a statin.20 When compared with
these data, our study suggests statin use has increased in
the UK. This increase is likely due to a multitude of
inﬂuences, including the NICE 2008 guidelines,21 land-
mark trials such as the Stroke Prevention by Aggressive
Reduction in Cholesterol Level (SPARCL) study which
demonstrated the beneﬁts of statins in the postischaemic
stroke population,22 and incorporation of statins and
lipid monitoring as quality measures in major
pay-for-performance initiatives in the UK.23
The continued recommendation for statin therapy for
the ASCVD population from the 2008 to the 2014 NICE
guidelines7 21 suggest that the 21% rate of statin non-use
in this population is largely due to discontinuation, a
hypothesis that is supported by our ﬁndings which indi-
cate that ∼60% of statin non-use in the ASCVD popula-
tion can be attributed to discontinuation (hence overall
13% (=21%×60%) of statin non-use in ASCVD popula-
tion is estimated to be due to discontinuation). High
rates of statin discontinuation have been documented in
the literature. For example, in a UK primary care data-
base analysis representing the 1997–2006 time period,
20% of patients initiated on a statin after an MI discon-
tinued therapy at 1 year.24 For the non-ASCVD
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population, the higher observed rate of statin non-use
(38%) likely reﬂects statin discontinuation and many
patients who have never been prescribed LMT. Our
study suggests that ∼59% of statin non-use in the
non-ASCVD population can be attributed to non-
initiation of LMT therapy. Prior to the 2014 NICE guide-
lines, some of these patients may not have qualiﬁed for
LMT due to higher risk thresholds in the NICE 2008
guidelines and the absence of certain conditions such as
CKD as a stand-alone criterion for statin therapy.7 21
Limitations
Availability of demographic and clinical characteristics
was limited to information available in the GP database.
Certain data such as Body Mass Index, ethnicity, blood
pressure and smoking status were not available for all
patients. Lipid measurements were not prospectively
speciﬁed and the study cohort represents individuals
with an available lipid proﬁle measurement, introducing
the possibility of bias in ﬁndings. The deﬁnition of LMT
usage at the time of lipid measurements was optimised
to provide valid ‘on-treatment’ measures, but ensuring
whether patients fully took their prescribed medications
was not feasible from the database.
For consistency, we based LMT categorisation on the
statin type and dose, regardless of concomitant non-
statin medications. This meant, for example, atorvastatin
10 mg + ezetimibe was categorised under medium-
potency statin, even though its overall lipid-lowering efﬁ-
cacy is close to atorvastatin 80 mg. NICE 2014 guidelines
speciﬁcally recommend atorvastatin 80 mg and atorvasta-
tin 20 mg, respectively, for the ASCVD and non-ASCVD
populations considered in our study. During LMT
categorisation, we included equivalent or higher potency
statin therapy in order to include situations where
quality of care with lipid-lowering treatment was similar
or better. Of those treated with NICE 2014 guidelines
according to our deﬁnition, 92% received atorvastatin
80 mg in the ASCVD population and 44% received ator-
vastatin 20 mg in the non-ASCVD population. Lower
doses of atorvastatin are allowed by the guidelines in
case of potential drug interactions, high risk of adverse
effects and patient preference; but estimation of how
frequently these cases occur was not feasible. In indivi-
duals ≥85 years of age, NICE 2014 guidelines recom-
mend a careful consideration of patient-level factors
informing the risk–beneﬁt of statin treatment and inten-
sity. Among those not treated according to NICE 2014
guidelines in our study, ∼14% and 10% individuals
within the ASCVD and non-ASCVD populations, respect-
ively, were ≥85 years of age.
Our study was focused on the secondary prevention
and high-risk primary-prevention populations; it did not
include those for whom treatment would be recom-
mended for treatment based solely on a QRISK2 10-year
risk of ≥10%. Thus, the analysis does not assess the full
impact of the guidelines across all indications.
CONCLUSIONS
In the UK, although 79% and 62% of patients with
ASCVD and high-risk patients without ASCVD, respect-
ively, received treatment with statin therapy in 2014,
there existed a large gap in terms of treatment concord-
ance with the NICE 2014 guidelines recommendations
released during the same year, with up to 90% of both
populations requiring modiﬁcation to their existing
therapy. Extrapolating these results to the UK popula-
tion, up to 3 million ASCVD and 3 million high-risk
non-ASCVD individuals (ie, fulﬁlling DM-based and/or
CKD-based guideline criteria) might require either
statin uptitration or initiation in order to attain full
concordance with NICE 2014 guidelines. Achievement
of ESC/EAS 2011 guideline criteria would also require
statin uptitration, as approximately two-thirds of indivi-
duals receiving moderate-intensity or high-intensity
statins were not at the recommended LDL-C goal.
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